Preoperative Multistrain Probiotic Supplementation Does Not Affect Body Weight Changes or Cardiometabolic Risk Factors in Bariatrics: Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Emerging evidence suggests that microbiota plays a crucial role in the development, progression, and therapeutic options in obesity and its comorbidities. This study assessed preoperative probiotic therapy's impact on bariatric treatment outcomes. A 12-week randomized, double-blind, placebo-con...

Full description

Saved in:
Bibliographic Details
Published in:Nutrients 2024-06, Vol.16 (13), p.2055
Main Authors: Potrykus, Marta, Czaja-Stolc, Sylwia, Stankiewicz, Marta, Szymański, Michał, Łoniewski, Igor, Kaska, Łukasz, Proczko-Stepaniak, Monika
Format: Article
Language:English
Subjects:
Adult
Analysis
Antibiotics
Bacteria
Bariatric Surgery
Bifidobacterium animalis subsp. lactis
Bifidobacterium bifidum
Body fat
Body mass index
Body Weight
body weight changes
Care and treatment
Clinical trials
Diagnosis
Dietary Supplements
Double-Blind Method
Female
Gastrointestinal Microbiome
Gastrointestinal surgery
Health aspects
Humans
Insulin resistance
Lactobacillus acidophilus
Lactococcus lactis
Male
Meals
Metabolism
Microbiota
Microorganisms
Middle Aged
Neurological disorders
Obesity
Obesity - surgery
Patient outcomes
Patients
Peptides
Physiological aspects
Preoperative Care - methods
Probiotics
Probiotics - administration & dosage
Probiotics - therapeutic use
risk
Risk factors
Surgery
Surgical outcomes
Treatment Outcome
Weight control
Weight Loss
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Emerging evidence suggests that microbiota plays a crucial role in the development, progression, and therapeutic options in obesity and its comorbidities. This study assessed preoperative probiotic therapy's impact on bariatric treatment outcomes. A 12-week randomized, double-blind, placebo-controlled trial with 48 patients undergoing bariatric surgery was conducted. Participants received probiotics-Sanprobi Barrier-which contained nine strains of bacteria: W23, W51 and W52, W37, W63, W56, W24, W19, and W58. Primary outcomes included excess body weight loss, body weight loss, and excess body mass index loss, with secondary objectives focusing on metabolic profiles. Surgical treatment of obesity significantly improved anthropometric and metabolic parameters. No significant differences were observed in primary outcomes or in secondary outcomes between groups at any time point post-surgery. Preoperative probiotics administration did not affect clinical outcomes 1, 3, or 6 months following bariatric surgery.
ISSN:2072-6643
2072-6643
DOI:10.3390/nu16132055